BIOMAT Database Logo BIOMAT Database Logo

[Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study]. 1979

H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche

UI MeSH Term Description Entries
D007383 Intermittent Claudication A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE. Claudication, Intermittent
D009257 Nafronyl A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors. Nafronyloxalate,Naftidrofuryl,Artocoron,Azunaftil,Di-Actane,Dusodril,Gévatran,LS-121,Nafronyl Oxalate,Nafti Von Ct,Nafti-Puren,Nafti-Ratiopharm,Naftifurin Oxalate,Naftilong,Naftilux,Praxilene,Praxilène,Di Actane,LS 121,LS121,Nafti Puren,Nafti Ratiopharm,NaftiRatiopharm,Oxalate, Nafronyl,Oxalate, Naftifurin
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005263 Femoral Artery The main artery of the thigh, a continuation of the external iliac artery. Common Femoral Artery,Arteries, Common Femoral,Arteries, Femoral,Artery, Common Femoral,Artery, Femoral,Common Femoral Arteries,Femoral Arteries,Femoral Arteries, Common,Femoral Artery, Common
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001157 Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Obstructive Diseases,Arterial Occlusion,Arterial Obstructive Disease,Arterial Occlusions,Arterial Occlusive Disease,Disease, Arterial Obstructive,Disease, Arterial Occlusive,Obstructive Disease, Arterial,Occlusion, Arterial,Occlusive Disease, Arterial

Related Publications

H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Therapy of arterial occlusive diseases with Dusodril].
July 1974, Fortschritte der Medizin,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[First clinical experiences with Dusodril in arterial occlusive diseases].
May 1968, Hippokrates,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Therapy of arterial occlusive diseases. The effect of bencyclan in trained patients with peripheral arterial occlusive disease (Double-blind study)].
July 1978, Fortschritte der Medizin,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
February 1980, Fortschritte der Medizin,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
Modafinil: a double-blind multicentric study.
December 1994, Sleep,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
March 1984, MMW, Munchener medizinische Wochenschrift,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
February 1979, Die Medizinische Welt,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Effectiveness of intravenous infusion treatment of peripheral arterial occlusive disease with Trental--results of a multicenter double-blind study].
January 1987, VASA. Supplementum,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[When are vasodilator agents effective in arterial occlusive diseases? Plethysmographic measurements in a double blind trial].
August 1969, Die Medizinische Welt,
H M Becker, and O Elert, and R Häring, and P C Maurer, and D Raithel, and M Sperling, and U Stockmann, and L W Storz, and H Hirche
[Double-blind study on piribedil in peripheral arterial diseases].
May 1976, Minerva medica,
Copied contents to your clipboard!